Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2009

Recently Spun Out Axikin Obtains $3M Series A Financing

  • Axikin Pharmaceuticals will receive $3 million through a series A private placement of its stock. The company was formed as a spinout from Actimis Pharmaceuticals following the acquisition of Actimis' lead program by Boehringer Ingelheim in a structured buyout in June 2008.

    Axikin's pipeline includes an advanced preclinical program with multiple small molecule lead candidates and two additional novel target research programs. These programs are expected to have broad applications across respiratory and allergic diseases including asthma, allergic rhinitis, and COPD.

    The financing was led by Sanderling Ventures, and additional investors included Mitsui & Co. Venture Partners.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »